Trump Plans 100% Tariff on Generic Drugs by 2028
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump announced plans to impose a 100% tariff on imported generic medicines starting August 2028, rising to 200% in August 2029 — months after the end of his second term.
- The administration had previously said generic drugs would be exempted from tariffs, marking a reversal of stated policy.
- Doctors and supply chain experts have sharply criticized the idea, warning it would raise costs, spur rationing, and cause shortages of crucial drugs.
- Indian drugmakers are the largest source of generic therapies for the U.S., with Indian medicines accounting for more than half of all U.S. prescriptions for birth control, antidepressants, and hypertension treatments in 2024.
- India, often dubbed the "pharmacy of the world," hosts the highest number of FDA-approved manufacturing plants outside the U.S.
- Trump has repeatedly threatened steep pharmaceutical tariffs in the past but has not previously followed through on imposing them.
Why it matters: The 100% tariff wouldn't even begin until August 2028 and would double to 200% after Trump leaves office, signaling this is a long-dated threat rather than immediate policy. Indian drugmakers — who supply the majority of US prescriptions for birth control, antidepressants, and hypertension treatments — face the most direct exposure if the threat ever materializes, and the administration's prior promise that generics would be exempted has now been reversed.
